中文名: | 4-[2-氨基-6-[(1R)-1-[4-氯-2-(3-甲基-1H-吡唑-1-基)苯基]-2,2,2-三氟乙氧基]-4-嘧啶基]-L-苯丙氨酸乙酯 N-苯甲酰甘氨酸盐;4-[2-氨基-6-[(1R)-1-[4-氯-2-(3-甲基-1H-吡唑-1-基)苯基]-2,2,2-三氟乙氧基]-4-嘧啶基]-L-苯丙氨酸乙酯-N-苯甲酰甘氨酸盐 |
中文别名: | |
英文名称: | LX1606 |
英文别名: | LX1606 |
CAS No.: | 1137608-69-5 |
分子式: | C27H26ClF3N6O3.C9H9NO3 |
分子量: | 754.15 |
性状: | |
储存: | |
安全术语: | |
风险术语: | |
危险品标志: | |
危险品运输编号: | |
用途: | LX1606 is an orally bioavailable, small-molecule, tryptophan hydroxylase (TPH) inhibitor prodrug with potential antiserotonergic activity. Upon administration, LX1606 is converted to its active metabolite LP-778902, which binds to and blocks the activity of TPH. This may result in a reduction in peripheral serotonin (5-HT) production and improvement of serotonin-mediated gastrointestinal effects such as severe diarrhea. TPH, the rate-limiting enzyme in serotonin biosynthesis, is overexpressed in carcinoid tumor cells. [1] |